Despite predictions of Revance Therapeutics outperforming in...
Despite predictions of Revance Therapeutics outperforming industry revenue growth, anticipated losses for next year have increased, hinting at future challenges. Significant forecast downgrades may amplify market skepticism towards the business.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Analysts Just Cut Their EPS Forecasts Substantially
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3205Followers
0Following
7975Visitors
Follow